More than 1,400 adults participated in Novo Nordisk’s phase 3 trial, which included lifestyle interventions such as reduced calorie intake and increased physical activity. Participants were divided into three groups: one receiving a placebo, another receiving 2.4-milligram injections (the highest currently approved dose), and a third receiving 7.2-milligram injections.
At the start of the 72-week study, participants’ mean body weight was approximately 250 pounds. Adults in the 7.2 milligram group experienced an average 18.7% weight reduction, compared to 15.6% in the 2.4 milligram group and 3.9% in the placebo group.
With perfect adherence to the regimen, researchers estimated weight loss would be 20.7% for the 7.2 milligram group, 17.5% for the 2.4 milligram group and 2.4% for the placebo group.
Novo Nordisk announced the study results on Jan. 17 and stated that additional findings will be presented at a scientific conference in 2025.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.